Nicholas Corcoran Sells 3,222 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 3,222 shares of the business’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $129.91, for a total value of $418,570.02. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $2,741,750.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

TransMedics Group Trading Down 0.0 %

Shares of NASDAQ TMDX traded down $0.06 during midday trading on Wednesday, hitting $127.22. 637,458 shares of the company traded hands, compared to its average volume of 769,221. The stock has a 50-day moving average price of $87.41 and a 200 day moving average price of $78.57. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. The firm has a market cap of $4.19 billion, a P/E ratio of -374.35 and a beta of 1.87. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $132.96.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company’s revenue for the quarter was up 132.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.08) earnings per share. As a group, analysts expect that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. FMR LLC increased its holdings in TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after buying an additional 1,407,171 shares during the last quarter. Eventide Asset Management LLC increased its stake in shares of TransMedics Group by 1,271.7% in the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock worth $50,663,000 after purchasing an additional 857,895 shares in the last quarter. Mackenzie Financial Corp purchased a new position in TransMedics Group during the fourth quarter valued at $35,804,000. Wasatch Advisors LP bought a new stake in TransMedics Group during the first quarter valued at about $32,162,000. Finally, Bank of New York Mellon Corp raised its position in shares of TransMedics Group by 91.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after purchasing an additional 363,012 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMDX has been the topic of a number of recent research reports. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Morgan Stanley boosted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Piper Sandler restated an “overweight” rating and issued a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. Finally, TD Cowen increased their price target on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.